ROAD MAP
2023
Named as one of the Top Ten Drug Discovery
Total funding raised Dec 2022
CancerAppy closed 2022 with €1.3M total raised.
2022
CA05 Lead Identification
We have identified insilico, several compounds as inhibitors of CA05, which is a protein kinase overexpressed in various types of tumors with a clear oncogenic role and no type-specific inhibitor, and we have started in vitro trials to select a lead.
CA04 Antidoby vs Pancreatic cancer
We have begun the development of an antibody (CA04 project) against a specific target validated in pancreatic cancer.
CA02/03 Target Identification vs NSCLC
CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies
Total Funding Raised
CancerAppy closed 2021 with €690K total raised.
2021
CA01 Target Identification vs TNBC
Together with our collaborators, we have found a new therapeutic target for TNBCs that we are currently patenting..
Torres Quevedo Grant
The Ministry of Science and Technology has granted Torres Quevedo research grant for our researcher Elisa Poyatos.
Pre-seed round
CancerAppy raised a pre-seed round of € 50K
Enisa Loan – 100K
Enisa has granted us a loan of 100K
4YFN 2021
Cancerappy has been selected to participate in the Espacio España 4YFN 2021.
Gene Report 1.0
We released GeneReport 1.0
2020
Neotec 2020
Cancerappy obtained the positive resolution of the Neotec 2020 program.
B-Venture 2020
CancerAppy was one of the 24 projects selected to exhibit at the B-venture 2020 Bilbao.
Versin 6.0 AI 1.0
AI + Drug Interaction / Personalized Medicine
Pre-seed Round 120K
CancerAppy raised a pre-seed round of € 120K
Version 5.0 dev
Code rewritten. Drug Interaction
2019
Version 4.0 dev
Tested at 6 hospitals and universities
CancerAppy begins
Cancerappy is founded in Bilbao as a startup